دورية أكاديمية
Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis.
| العنوان: | Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis. |
|---|---|
| المؤلفون: | Lastuvkova H; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Nova Z; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Hroch M; Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Alaei Faradonbeh F; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Schreiberova J; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Mokry J; Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Faistova H; Department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Stefela A; Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Dusek J; Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Kucera O; Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Hyspler R; Institute of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Kralove, Czech Republic., Dohnalkova E; Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Bayer RL; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Hirsova P; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Pavek P; Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic., Micuda S; Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. |
| المصدر: | Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2023 Nov 28; Vol. 196 (2), pp. 200-217. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9805461 Publication Model: Print Cited Medium: Internet ISSN: 1096-0929 (Electronic) Linking ISSN: 10960929 NLM ISO Abbreviation: Toxicol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : Cary, NC : Oxford University Press Original Publication: Orlando, FL : Academic Press, c1998- |
| مواضيع طبية MeSH: | Non-alcoholic Fatty Liver Disease*/metabolism, Humans ; Male ; Animals ; Mice ; Bile Acids and Salts/metabolism ; Carvedilol/pharmacology ; Carvedilol/metabolism ; Mice, Inbred C57BL ; Liver ; Membrane Transport Proteins/metabolism ; Homeostasis |
| مستخلص: | Carvedilol is a widely used beta-adrenoreceptor antagonist for multiple cardiovascular indications; however, it may induce cholestasis in patients, but the mechanism for this effect is unclear. Carvedilol also prevents the development of various forms of experimental liver injury, but its effect on nonalcoholic steatohepatitis (NASH) is largely unknown. In this study, we determined the effect of carvedilol (10 mg/kg/day p.o.) on bile formation and bile acid (BA) turnover in male C57BL/6 mice consuming either a chow diet or a western-type NASH-inducing diet. BAs were profiled by liquid chromatography-mass spectrometry and BA-related enzymes, transporters, and regulators were evaluated by western blot analysis and qRT-PCR. In chow diet-fed mice, carvedilol increased plasma concentrations of BAs resulting from reduced BA uptake to hepatocytes via Ntcp transporter downregulation. Inhibition of the β-adrenoreceptor-cAMP-Epac1-Ntcp pathway by carvedilol may be the post-transcriptional mechanism underlying this effect. In contrast, carvedilol did not worsen the deterioration of BA homeostasis accompanying NASH; however, it shifted the spectra of BAs toward more hydrophilic and less toxic α-muricholic and hyocholic acids. This positive effect of carvedilol was associated with a significant attenuation of liver steatosis, inflammation, and fibrosis in NASH mice. In conclusion, our results indicate that carvedilol may increase BAs in plasma by modifying their liver transport. In addition, carvedilol provided significant hepatoprotection in a NASH murine model without worsening BA accumulation. These data suggest beneficial effects of carvedilol in patients at high risk for developing NASH. (© The Author(s) 2023. Published by Oxford University Press on behalf of the Society of Toxicology.) |
| References: | Toxicol Appl Pharmacol. 2015 Feb 15;283(1):57-64. (PMID: 25582706) Cell Metab. 2021 Apr 6;33(4):791-803.e7. (PMID: 33338411) Anal Biochem. 2013 Feb 15;433(2):105-11. (PMID: 23085117) Drug Chem Toxicol. 2021 Jan;44(1):101-111. (PMID: 30810389) Biochem Biophys Res Commun. 2013 Aug 9;437(4):597-602. (PMID: 23850676) Int J Mol Sci. 2021 Jun 16;22(12):. (PMID: 34208774) Mol Biol Cell. 2011 Oct;22(20):3902-15. (PMID: 21865596) Pharmacogenet Genomics. 2014 Oct;24(10):522-6. (PMID: 25121519) Front Pharmacol. 2023 Jan 26;14:1116422. (PMID: 36778021) Int J Mol Sci. 2020 Nov 27;21(23):. (PMID: 33261044) J Steroid Biochem Mol Biol. 2020 Sep;202:105702. (PMID: 32505574) Dig Dis Sci. 2013 Jun;58(6):1602-14. (PMID: 23371010) Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Dec;1862(12):1469-1480. (PMID: 28888833) Front Pharmacol. 2021 Aug 13;12:713149. (PMID: 34483922) Int J Pharm. 2022 Jan 5;611:121302. (PMID: 34793935) Biomed Pharmacother. 2018 Dec;108:1617-1627. (PMID: 30372864) Methods. 2018 Oct 1;149:49-58. (PMID: 29704662) Front Physiol. 2018 Nov 13;9:1593. (PMID: 30483153) Eur J Pharm Sci. 2017 Nov 15;109S:S108-S115. (PMID: 28522373) World J Gastroenterol. 2014 Jul 14;20(26):8525-34. (PMID: 25024607) JAMA. 2020 Mar 24;323(12):1175-1183. (PMID: 32207804) Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295) Biochem Biophys Res Commun. 2009 Mar 20;380(4):818-22. (PMID: 19338759) PLoS One. 2016 Feb 18;11(2):e0148868. (PMID: 26891124) PLoS One. 2013 Sep 03;8(9):e72928. (PMID: 24019886) FASEB J. 2021 Jan;35(1):e21271. (PMID: 33368684) Am J Physiol Endocrinol Metab. 2021 Jul 1;321(1):E90-E104. (PMID: 34029162) Life Sci. 2019 Apr 1;222:175-182. (PMID: 30826497) Cell Physiol Biochem. 2019;52(6):1427-1445. (PMID: 31088037) Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6409-14. (PMID: 15096593) J Chromatogr A. 2023 Aug 30;1705:464173. (PMID: 37392639) Hepatol Res. 2014 May;44(5):560-70. (PMID: 23607506) J Clin Exp Hepatol. 2019 Nov-Dec;9(6):723-730. (PMID: 31889754) GE Port J Gastroenterol. 2019 May;26(3):196-201. (PMID: 31192288) Biomed Res Int. 2017;2017:4612769. (PMID: 28396867) Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. (PMID: 27743861) F1000Res. 2017 Nov 20;6:2029. (PMID: 29188025) Hepatology. 2017 Jan;65(1):350-362. (PMID: 27358174) J Lipid Res. 2020 Mar;61(3):291-305. (PMID: 31506275) Toxicol Sci. 2014 Oct;141(2):538-46. (PMID: 25055961) Lancet. 2019 Apr 20;393(10181):1597-1608. (PMID: 30910320) Hepatology. 2006 Oct;44(4):865-73. (PMID: 17006923) Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5813-5820. (PMID: 29272018) World J Gastroenterol. 2020 Sep 14;26(34):5101-5117. (PMID: 32982112) Eur J Pharm Sci. 2017 Aug 30;106:302-312. (PMID: 28603032) Drug Des Devel Ther. 2019 Aug 01;13:2667-2676. (PMID: 31534314) Cells. 2020 Nov 24;9(12):. (PMID: 33255185) Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G316-24. (PMID: 12702492) Mol Med Rep. 2019 Aug;20(2):1605-1612. (PMID: 31257490) Am J Physiol. 1997 Oct;273(4):G842-8. (PMID: 9357825) Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G84-G98. (PMID: 31657225) |
| معلومات مُعتمدة: | R01 DK130884 United States DK NIDDK NIH HHS; R01DK130884 United States DK NIDDK NIH HHS |
| فهرسة مساهمة: | Keywords: bile acids; carvedilol; nonalcoholic steatohepatitis |
| المشرفين على المادة: | 0 (Bile Acids and Salts) 0K47UL67F2 (Carvedilol) 0 (Membrane Transport Proteins) |
| تواريخ الأحداث: | Date Created: 20230826 Date Completed: 20231129 Latest Revision: 20240612 |
| رمز التحديث: | 20240612 |
| مُعرف محوري في PubMed: | PMC10682974 |
| DOI: | 10.1093/toxsci/kfad088 |
| PMID: | 37632784 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1096-0929 |
|---|---|
| DOI: | 10.1093/toxsci/kfad088 |